Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients

详细信息    查看全文

• 作者：Mahdiyar Iravani Saadi ; Ramin Yaghobi ; Mohammad Hossein Karimi…
• 关键词：Cytomegalovirus ; HSCT ; GVHD ; Costimulatory molecules
• 刊名：Molecular Biology Reports
• 出版年：2013
• 出版时间：October 2013
• 年：2013
• 卷：40
• 期：10
• 页码：5833-5842
• 全文大小：349KB
• 参考文献：1. Husain S, Pietrangeli CE, Zeevi A (2009) Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 21:1- CrossRef
  2. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD (2012) After allogeneic marrow transplantation cytomegalovirus antigen detection in peripheral blood leukocyte. Blood 80:1358-364
  3. Yaghobi R, Behbahani AB, Sabahi F, Roustaee MH, Alborzi A, Ramzi M, Nourani H (2005) Comparative analysis of a double primer PCR assay with plasma, leukocytes and antigenemia for diagnosis of active human cytomegalovirus infection in bone marrow transplant patients. Bone Marrow Transplant 35:595-99 CrossRef
  4. Rubin RH (2007) The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the ‘silo hypothesis- Curr Opin Infect Dis 20:399-07 CrossRef
  5. Kamar N, Mengelle C, Rostaing L (2007) Alteration of direct and indirect effects of cytomegalovirus. Exp Clin Transplant 5:727-30
  6. Karimi MH, Motazedian M, Geramizadeh B, Nikeghbalian S, Yaghobi R, Abedi F, Aghdaee MH, Azarpira N, Arabpour M, Malekpour Z, Namayandeh M (2011) Association of the co-stimulatory molecules polymorphisms with CMV infection in liver transplant recipients. Int J Organ Transplant Med 2:170-77
  7. Douroudis K, Laine AP, Heinonen M, Hermann R, Lipponen K, Veijola R, Simell O, Knip M, Uibo R, Ilonen J, Kisand K (2009) Association of CTLA4 but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates. Hum Immunol 70:536-39 CrossRef
  8. Dariavach P, Mattéi MG, Golstein P, Lefranc MP (1988) Human Ig superfamily CTLA4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA4 cytoplasmic domains. Eur J Immunol 18:1901-905 CrossRef
  9. Ghaderi A (2011) CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol 8:127-49
  10. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, Fennelly JA, Vowles C, Hanke T, Walse B, Hünig T, S?rensen P, Stuart DI, Davis SJ (2005) Crystal structure of a soluble CD28–Fab complex. Nat Immunol 6:271-79 CrossRef
  11. Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739-45 CrossRef
  12. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-72 CrossRef
  13. Inman BA, Frigola X, Dong H, Kwon ED (2007) Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 7:15-0 CrossRef
  14. Wu J, Tang JL, Wu SJ, Lio HY, Yang YC (2009) Functional polymorphism of CTLA4 and ICOS genes in allogeneic hematopoietic stem cell transplantation. Clin Chim Acta 403:229-33 CrossRef
  15. Ogawa S, Nagamatsu G, Watanabe M, Watanabe S, Hayashi T, Horita S, Nitta K, Nihei H, Tezuka K, Abe R (2001) Opposing effects of anti-activation inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J Immunol 167:5741-748
  16. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR (2005) Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 10:3372-380 CrossRef
  17. Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D, O’Brien SJ, Astemborski J, Thomas DL (2004) Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 78:11258-1262 CrossRef
  18. Schott E, Witt H, Pascu M, van Boemmel F, Weich V, Bergk A, Halangk J, Müller T, Puhl G, Wiedenmann B, Berg T (2007) Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol 19:947-51 CrossRef
  19. Pons Mi?ano JA, Ramírez Romero P, Robles Campos R, Sánchez Bueno F, Parrilla Paricio P (2007) Tolerance and chimerism in liver transplantation. Rev Esp Enferm Dig 99:343-50 CrossRef
  20. Zhang G, Liu Z, Duan S, Han Q, Li Z, Lv Y, Chen J, Lou S, Li N (2010) Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol 71:1209-213 CrossRef
  21. Pérez-García A, De la Cámara R, Román-Gómez J, Jiménez-Velasco A, Encuentra M, Nieto JB, de la Rubia J, Urbano-Ispizúa A, Brunet S, Iriondo A, González M, Serrano D, Espigado I, Solano C, Ribera JM, Pujal JM, Hoyos M, Gallardo D (2007) CTLA4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 110:461-67 CrossRef
  22. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, Nishimura H, Taylor PA (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272-277
  23. Schilbach K, Schick J, Wehrmann M, Wollny G, Simon P, Schlegel PG, Eyrich M (2007) PD-1–PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine GVHD across minor histocompatibility antigen barriers. Transplantation 84:214-22 CrossRef
  24. Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC (2007) Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant 7:2683-692 CrossRef
  25. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ (2007) Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195:633-44 CrossRef
  26. La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye A, Diamond DJ, Schilbach K, Schick J, Wehrmann M, Wollny G, Simon P, Schlegel PG, Eyrich M (2008) Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 197:25-3 CrossRef
  27. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M (2008) PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 8:1486-497 CrossRef
  28. Ghislaine M, Hawkins G, Thao L, Palmer J, Dagis A, Li X, Franck AE, Tegtmeier B, Lacey SF, Diamond DJ, Forman SJ, Zaia JA (2009) Increased PD-1 expression in CMV disease and acute GVHD after allogeneic HCT. Biol Blood Marrow Transplant 15:872-80 CrossRef
  29. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18:295-04 CrossRef
  30. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone marrow transplantation. New Engl J Med 292:895-02 CrossRef
  31. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM (1997) IBMTR Severity Index for grading graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97:855-64 CrossRef
  32. Miller S, Seet H, Khan Y, Wright C, Nadarajah R (2010) Comparison of QIAGEN automated nucleic acid extraction methods for CMV quantitative PCR testing. Am J Clin Pathol 133:558-63 CrossRef
  33. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y (1999) A soluble form of CTLA4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 29:3596-602 CrossRef
  34. Alizadeh MAH, Hajilooi M, Ranjbar M, Fallahian F, Mousavi SM (2006) Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 12:630-35
  35. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C (2010) +49A/G polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 71:83-7 CrossRef
  36. Azarian M, Busson M, Lepage V, Charron D, Toubert A, Loiseau P, de Latour RP, Rocha V, Socié G (2007) Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations. Blood 110:4623-624 CrossRef
  37. Pérez-García A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R, Ribera JM, Heras I, Llorente A, Hoyos M, Esteve J, Besalduch J, Bueno J, Sierra J, Gallardo D, Grupo cooperativo para el estudio y tratamiento de las leucemias agudas (2009) CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 23:486-91 CrossRef
  38. Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, Xu C, Chen Z (2010) Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 37:515-20 CrossRef
  39. Duan S, Zhang G, Han Q, Li Z, Liu Z, Chen J, Lv Y, Li N, Wang Y, Li M, Lou S, Yang M, Zhu Q, Xing F (2011) CTLA4 exon 1 +49 polymorphism alone and in a haplotype with 2318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol Biol Rep 38:5125-132 CrossRef
  40. De Reuver P, Pravica V, Hop W, Boor P, Metselaar HJ, Hutchinson IV, Tilanus HW, Kwekkeboom J (2003) Recipient CTLA4 +49 G/G genotype is associated with reduced incidence of acute rejection after liver transplantation. Am J Transplant 3:1587-594 CrossRef
  41. Chen L (2004) Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-47 CrossRef
  42. Serriari N-E, Gondois-Rey F, Guillaume Y, Remmerswaal EBM, Pastor S, Messal N, Truneh A, Hirsch I, van Lier RA, Olive D (2010) Infection and regulates their function expressed on CMV-specific T cells during B and T lymphocyte attenuator is highly. J Immunol 185:3140-148 CrossRef
  43. Leng Q, Bentwich Z, Borkow G (2002) CTLA-4 upregulation during aging. Mech Ageing Dev 123:1419-421 CrossRef
  
• 作者单位：Mahdiyar Iravani Saadi (1) (2)
  Ramin Yaghobi (1)
  Mohammad Hossein Karimi (1)
  Bita Geramizadeh (1)
  Mani Ramzi (3)
  Maryam Zakerinia (3)
  
  1. Shiraz Transplant Research Center, Namazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
  2. Islamic Azad University, Jahrom Branch, Jahrom, Iran
  3. Hematology Research Center and Bone Marrow Transplant Unit, Shiraz University of Medical Sciences, Shiraz, Iran
  
• ISSN：1573-4978

文摘

Determinative associations may exist between costimulatory molecule gene polymorphisms with a variety of post hematopoietic stem cell transplantation (HSCT) viral related clinical outcomes especially acute graft versus host disease (aGVHD). Therefore in this study the associations between costimulatory molecule gene polymorphisms including: cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death-1 (PD-1), inducible T cell costimulator (ICOS), and cluster differentiation 28 (CD28) with active cytomegalovirus (CMV) infection were evaluated in HSCT patients. The 72 allogeneic HSCT patients with and without aGVHD were enrolled in this cross sectional study between years: 2004-011. The single nucleotide polymorphisms in loci of the costimulatory molecules including: CTLA4 gene (?18 C/T, 1722 T/C, 1661 A/G, +49 A/G), PD-1 gene (PD-1.3 A/G, PD-1.9 C/T), ICOS gene (1720 C/T), and CD28 gene (+17 C/T) were analyzed in studied HSCT patients by PCR-RFLP methods. The active CMV infection was evaluated in fresh EDTA-treated blood samples of each allogeneic HSCT patients by CMV antigenemia kit according to manufacturer’s instruction. Active CMV infection was found in 11 of 72 (15.27?%) of allogeneic HSCT patients. The T allele and TT genotype of the CD28 +17 C/T were significantly higher frequency in active CMV infected allogeneic HSCT patients experienced aGVHD. The G allele and GG genotype of the CTLA4 ?661 A/G were significantly higher frequent in active CMV infected allogeneic HSCT patients experienced low grade of aGVHD. Finally, finding of significant associations between CD28 +17 C/T and CTLA4 ?661 A/G genotypes with CMV active infection in allogeneic HSCT patients experienced aGVHD emphasize on the importance of the genetic pattern of costimulatory genes in outcomes of active CMV infection in HSCT patients needs completed studies.